Multinational pharmaceutical and medical equipment companies will bring a variety of innovative medical solutions that integrate cutting-edge technologies and clinical insights to the seventh China International Import Expo to be held in Shanghai in early November.
They said they are resolute in bringing the top echelon of innovative products and technologies to China at the fastest speed possible, aiming to help promote the innovation and development of techniques regarding disease diagnosis and treatment, and contribute to the country’s medical and health undertakings.
Siemens Healthineers’ flagship artificial intelligence-empowered cardiovascular ultrasound system, ACUSON Origin, will make its China debut at CIIE. The German company said that ACUSON Origin’s AI capabilities are trained on the world’s largest cardiac image database with 2 billion cardiac images, providing more than 5,600 AI-automated ultrasound measurements.
ACUSON Origin’s fully integrated AI solutions, high-definition image quality, convenient intelligent operation and diversified examination methods, reduce differences between doctors, improve accuracy and consistency of diagnostic results, and help ultrasound users accurately evaluate various cardiovascular diseases, said the company.
Also, to address the challenge of coronary heart diseases, Siemens Healthineers has worked with a domestic innovator and will launch the world’s first integrated multi-modality therapy platform at CIIE.
The platform unprecedentedly combines the intra-vascular images generated through Digital Subtraction Angiography (DSA) and Optical Coherence Tomography (OCT) to provide clinicians with comprehensive vascular information ranging from anatomy to functional medicine, while treating a coronary heart disease. It empowers clinicians to complete precise, individualized heart stent surgeries, said the company.
The United States-based Abbott said it will unveil AVEIR™, the world’s first dual-chamber (DR) leadless pacemaker system, at CIIE.
Through Abbott’s proprietary i2i™ (implant-to-implant) communication technology, AVEIR DR devices provide synchronized cardiac pacing between two leadless pacemakers.
During the CIIE, the company will also launch FreeStyle Libre 2 System, a sensor-based system that provides real-time glucose readings to a smartphone without the need for finger pricks for diabetes patients. Enhanced features of this upgraded system include a Bluetooth connection and customizable real-time glucose alarms for more informed action.
French pharmaceutical company Sanofi’s booth will feature its global R&D pipeline including 12 potential blockbuster products and seven transformative therapies in the field of immunology.
They include Tzield, the world’s first and sole therapy that can postpone the onset of type 1 diabetes for nearly three years, and Dupixent, the world’s first approved targeted medicine for chronic obstructive pulmonary disease.
This year marks the 60th anniversary of Sino-French diplomatic relations. As one of the first multinational companies to enter China more than four decades ago, Sanofi has brought the country over 60 innovative medicines and vaccines, addressing seven of China’s 10 most life-threatening diseases, said Paul Hudson, CEO of Sanofi.
“China is one of the largest Sanofi markets today. Also, we have a deep appreciation for the scale and speed of innovation in China, and we look forward to supporting the growth of the world-class healthcare ecosystem here to benefit patients globally,” said Hudson.
zhouwenting@trulynews.cn